133 related articles for article (PubMed ID: 38296684)
1. Defining the prognostic value of urine extracellular vesicles ZNF540 in bladder cancer based on GEO database.
Lv HX; Wang D; Zhou FH
Asian J Surg; 2024 May; 47(5):2387-2388. PubMed ID: 38296684
[No Abstract] [Full Text] [Related]
2. Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles.
Oeyen E; Hoekx L; De Wachter S; Baldewijns M; Ameye F; Mertens I
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769831
[TBL] [Abstract][Full Text] [Related]
3. Urinary extracellular vesicles-encapsulated miRNA signatures: A new paradigm for urinary bladder cancer diagnosis and classification.
Kural S; Jain G; Agarwal S; Das P; Kumar L
Urol Oncol; 2024 Jul; 42(7):179-190. PubMed ID: 38594151
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle-invasive bladder cancer.
Baumgart S; Meschkat P; Edelmann P; Heinzelmann J; Pryalukhin A; Bohle R; Heinzelbecker J; Stöckle M; Junker K
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2725-2736. PubMed ID: 31552489
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.
Dugas SG; Müller DC; Le Magnen C; Federer-Gsponer J; Seifert HH; Ruiz C; Savic Prince S; Vlajnic T; Zellweger T; Mertz KD; Bacon JVW; Wyatt AW; Rentsch CA; Bubendorf L
Cancer Cytopathol; 2019 Sep; 127(9):578-585. PubMed ID: 31386310
[TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression.
Andreu Z; Otta Oshiro R; Redruello A; López-Martín S; Gutiérrez-Vázquez C; Morato E; Marina AI; Olivier Gómez C; Yáñez-Mó M
Eur J Pharm Sci; 2017 Feb; 98():70-79. PubMed ID: 27751843
[TBL] [Abstract][Full Text] [Related]
7. Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond.
Liu YR; Ortiz-Bonilla CJ; Lee YF
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30231589
[TBL] [Abstract][Full Text] [Related]
8. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer.
Konety BR; Nguyen TS; Brenes G; Sholder A; Lewis N; Bastacky S; Potter DM; Getzenberg RH
J Urol; 2000 Sep; 164(3 Pt 1):634-9. PubMed ID: 10953114
[TBL] [Abstract][Full Text] [Related]
10. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer.
Weikert S; Krause H; Wolff I; Christoph F; Schrader M; Emrich T; Miller K; Müller M
Int J Cancer; 2005 Nov; 117(2):274-80. PubMed ID: 15900578
[TBL] [Abstract][Full Text] [Related]
11. TERT mutations in urine could predict bladder cancer recurrence.
Gourd E
Lancet Oncol; 2017 Aug; 18(8):e443. PubMed ID: 28712514
[No Abstract] [Full Text] [Related]
12. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers.
Tomiyama E; Matsuzaki K; Fujita K; Shiromizu T; Narumi R; Jingushi K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Adachi J; Tomonaga T; Nonomura N
Cancer Sci; 2021 May; 112(5):2033-2045. PubMed ID: 33721374
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the VEGF level in urinary bladder carcinoma.
Sankhwar M; Sankhwar SN; Abhishek A; Rajender S
Cancer Biomark; 2015; 15(4):349-55. PubMed ID: 25792473
[TBL] [Abstract][Full Text] [Related]
15. Urine cytology. It is still the gold standard for screening?
Brown FM
Urol Clin North Am; 2000 Feb; 27(1):25-37. PubMed ID: 10696242
[TBL] [Abstract][Full Text] [Related]
16. High Detection Rate for Non-Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test.
Steinbach D; Kaufmann M; Hippe J; Gajda M; Grimm MO
Clin Genitourin Cancer; 2020 Jun; 18(3):210-221. PubMed ID: 32139301
[TBL] [Abstract][Full Text] [Related]
17. Urine markers for bladder cancer surveillance: a systematic review.
Ratliff TL
J Urol; 2005 Nov; 174(5):2065-6. PubMed ID: 16217395
[No Abstract] [Full Text] [Related]
18. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC
Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and Prognostic Markers in Bladder Cancer.
Ku JH; Kim WJ; Lerner SP; Chun F; Kluth LA
Dis Markers; 2016; 2016():2425091. PubMed ID: 27795607
[No Abstract] [Full Text] [Related]
20. UroMark-a urinary biomarker assay for the detection of bladder cancer.
Feber A; Dhami P; Dong L; de Winter P; Tan WS; Martínez-Fernández M; Paul DS; Hynes-Allen A; Rezaee S; Gurung P; Rodney S; Mehmood A; Villacampa F; de la Rosa F; Jameson C; Cheng KK; Zeegers MP; Bryan RT; James ND; Paramio JM; Freeman A; Beck S; Kelly JD
Clin Epigenetics; 2017; 9():8. PubMed ID: 28163793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
